Gatifloxacin derivatives: Synthesis, antimycobacterial activities, and inhibition of Mycobacterium tuberculosis DNA gyrase

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 11, 2006, Pages 2982-2985

  Sriram, Dharmarajan ^a   Aubry, Alexandra ^b   Yogeeswari, Perumal ^a   Fisher, L M ^c  

^a BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

^b SORBONNE UNIVERSITÉ   (France)

^c Division of Basic Medical Sciences   (United Kingdom)

Author keywords

Antimycobacterial; DNA gyrase inhibition; Gatifloxacin derivatives

Indexed keywords

1 CYCLOPROPYL 6 FLUORO 8 METHOXY 7 [[N4 [1' (5 ISATINYL BETA SEMICARBAZO)]METHYL] N1 PIPERAZINYL] 4 OXO 1,4 DIHYDRO 3 QUINOLINE CARBOXYLIC ACID; DNA TOPOISOMERASE (ATP HYDROLYSING); GATIFLOXACIN; GYRASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SCREENING; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; IC 50; IN VITRO STUDY; IN VIVO STUDY; LUNG PARENCHYMA; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; SPLEEN; TUBERCULOSIS; WILD TYPE;

ANIMALS; ANTITUBERCULAR AGENTS; DNA GYRASE; ENZYME INHIBITORS; FLUOROQUINOLONES; MICE; MOLECULAR STRUCTURE; MYCOBACTERIUM TUBERCULOSIS; STRUCTURE-ACTIVITY RELATIONSHIP;

ANIMALIA; BACTERIA (MICROORGANISMS); MYCOBACTERIUM TUBERCULOSIS;

EID: 33646481970     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.02.065     Document Type: Article

References (19)

1. Raviglione M.C. Tuberculosis 83 (2003) 4
2. Corbett E.L., Watt C.J., Walker N., Maher D., Williams B.G., Raviglione M.C., and Dye C. Arch. Intern. Med. 1639 (2003) 1009
3. Dye C., Scheele S., Dolin P., Pathania V., and Raviglione M.C. JAMA 282 (1999) 677
4. Bloom B.R., and Murray C.J.L. Science 257 (1998) 1055
5. Basso L.A., and Blanchard J.S. Adv. Exp. Med. Biol. 456 (1998) 115
6. World Health Organization, Anti-tuberculosis drug resistance in the world: Third Global Report, 2004.
7. Duncan K. Tuberculosis 83 (2003) 201
8. Sato K., Tomioka H., Sano C., Shimizu T., Sano K., Ogasawara K., Cai S., and Kamei T. J. Antimicrob. Chemother. 52 (2003) 199
9. Maxwell A. Trends Microbiol. 5 (1997) 102
10. Bozeman L., Burman W., Metchock B., Welch L., and Weiner M. Clin. Infect. Dis. 40 (2002) 386
11. Besra G.S., and Chatterjee D. Lipids and carbohydrates of Mycobacterium tuberculosis. In: Bloom B.R. (Ed). Tuberculosis (1994), ASM Press, Washington, DC 285
12. Sriram D., Yogeeswari P., Basha S.J., Radha D.R., and Nagaraja V. Bioorg. Med. Chem. 13 (2005) 5774
13. 6: C, 58.88; H, 5.11; N, 16.57. Found: C, 59.01; H, 5.09; N, 16.49.
14. Collins L.A., and Franzblau S.G. Antimicrob. Agents Chemother. 41 (1997) 1004
15. Takacs-Novak K., Noszal B., Hermecz I., Kereszturi G., Podanyi B., and Szasz G. J. Pharm. Sci. 79 (1990) 1023
16. Young D.B. Strategies for new drug development. In: Bloom B.R. (Ed). Tuberculosis (1994), ASM Press, Washington, DC 559
17. Gundersen L.L., Nissen-Meyer J., and Spilsberg B. J. Med. Chem. 45 (2002) 1383
18. Levine C.H., Hiasa A., and Marians K.J. Biochim. Biophys. Acta 1400 (1998) 29
19. Aubry A., Pan X.S., Fisher L.M., Jarlier V., and Cambau E. Antimicrob. Chemother. 48 (2004) 1281